



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L34230GJ1990PLC086581

Date: 30th July, 2026

To,
The Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400001.

Subject: Outcome of Board Meeting held on Thursday, July 30, 2026 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref.: Norris Medicines Limited, Script Code: 524414, ISIN: INE744C01029.

Dear Sir/ Madam,

On recommendation of Audit Committee and the Nomination and Remuneration Committee, pursuant to provisions of Section 203 of the Companies Act, 2013 read with rules made there under and SEBI LODR Regulations, the Board of Directors in their meeting held today i.e., 30th July, 2026, approved appointment of Mr. Iqbal Ismail Patel as Chief Financial Officer (CFO) and KMP of the Company w.e.f. 30th July, 2026.

The details required under Regulation 30 of the Listing Regulations read with applicable SEBI Circular(s) in respect of appointment of CFO and KMP, are enclosed herewith as **Annexure A**.

Board meeting's commencement time: 5:00 PM
Board meeting's concluded time: 5:30 PM

Kindly take the note of the above and acknowledge the receipt of the same.

For NORRIS MEDICINES LIMITED

VIMAL D. SHAH
DIRECTOR
DIN-01506655



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L34230GJ1999PLC086581

Annexure A

Details with respect to Regulation 30 read with Schedule III of the Listing Regulations, SEBI Circular SEBI Circular bearing Ref. No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Name of the Chief Financial Officer	Mr. Iqbal Ismail Patel
Reason for change Viz appointment, Resignation, removal, death or otherwise	Appointment as Chief Financial Officer of the Company.
Date of Appointment /re-appointment/cessation (as applicable) & term of appointment/re-appointment	<u>Date of Appointment:</u> 30 th July, 2026 <u>Term of appointment:</u> Mr. Iqbal Ismail Patel on such terms and condition including remuneration as may be mutually agreed between Mr. Iqbal Ismail Patel and the board of directors of the Company
Brief profile (In case of appointment)	Mr. Iqbal Ismail Patel has been associated with Norris Medicines Ltd for more than past 11 years and possesses rich experience in finance, accounts, taxation, budgeting, financial planning, and corporate management. He has played a significant role in the Company's financial operations and strategic initiatives in past. Mr. Iqbal Patel holds a Graduate degree.
Disclosure of relationship between Directors (in case of appointment)	He is not related to any of the Directors and Key Managerial Personnel of the Company.
Confirmation in compliance with SEBI Letter dated June 14, 2018 read along with Exchange Circular dated June 20, 2018 (Affirmation that the person proposed to be appointed as Director is not debarred from holding the office by virtue of any SEBI Order or any other authority)	NA.



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L34230GJ1990PLC086581

Affirmation that the Director being appointed is not disqualified from holding the office of director pursuant to provisions of Section 164 of the Companies Act, 2013

NA.

For NORRIS MEDICINES LIMITED

VIMAL D. SHAH
DIRECTOR
DIN-01506655